

INFORMATION SUMMARY FOR THE PUBLIC

Host Country:	Ecuador
Name of Borrowers:	Gamma Knife Ecuador (the “Borrower”)
Project Description:	This Project involves a seven-year, \$3.375 million OPIC loan to Gamma Knife Ecuador to finance the acquisition of outstanding equity ownership, upgrade of equipment, and working capital for an existing brain cancer treatment facility and unique clinic named <i>Gamma Knife Center Ecuador</i> located in Guayaquil, Ecuador (the :Project:). The Borrower offers medical services to detect and treat certain types of brain tumors, arteriovenous malformations, and other brain dysfunctions using cutting edge technology, that is both extremely accurate and has above average therapeutic response, and highly-qualified and experienced medical staff. The Project’s total cost is expected to be \$3.75 million, with the remaining financing coming from the investors in the form of equity. In 2009, a <i>Leksell Gamma Knife Machine Model 4C</i> was acquired by the Project from Elekta, which is the Swedish Company that owned the patent and developed new medical technologies, such as the non-invasive medical procedures that uses radioactive Cobalt-60. The first patient was successfully treated in October 2011. Since 2011, the Borrower has treated more than 1,000 patients and intends to upgrade or replace their current machine and resources within one year. The new technology implemented through the project will be <i>Leksell Gamma Knife Machine New Model Perfexion</i> recently developed by Elekta for an estimated cost of \$1.5 million available in the market.
Proposed OPIC Loan:	\$3,375,000 with a 7-year loan term, including a 12-month grace period on principal repayment.
Total Project Costs:	\$3,750,000
U.S. Sponsor:	Gamma Knife Financing, LLC (San Francisco, CA)
Foreign Sponsor:	N/A
Policy Review	
U.S. Economic Impact:	The Project is not expected to have a negative impact on the U.S. economy. There is no U.S. procurement associated with this Project, and therefore the Project is expected to have a neutral impact on U.S. employment. The Project is not expected to have an impact on the U.S. trade balance.
Developmental Effects:	This Project is expected to have a positive developmental impact by improving healthcare technology in Ecuador. The Project will finance the upgrade of equipment for the only GK center in the country, which treats brain cancer through a non-invasive radiosurgery and cutting edge technology that is both extremely

	<p>accurate and has an above average therapeutic response. The Project will offer services to over 250 private patients per year. Approximately 60% of the Borrower's clients are low-income. The Project aligns with the Government of Ecuador's Health National System and Policy, reformed and implemented in 2015, to improve access to quality health services across all income levels. The Project aligns with the Sustainable Development Goal No.3 which is "Good Health and Well-Being".</p>
Environment:	<p>Operation of a medical services facility in an existing hospital is screened as a Category B project under OPIC's environmental and social guidelines because impacts are site-specific and readily mitigated. The major issue of concern related to such projects is the quality of medical services performed. The Project will only provide radiation treatment to patients with tumors and vascular abnormalities in the brain with the hospital (in which the Project facility is located) providing all the clinical and waste management services. No surgery will be performed at the Project facility.</p>
Worker Rights:	[-]
Human Rights:	[-]